Raymond F Vennare Net Worth

The estimated Net Worth of Raymond F Vennare is at least $79.5 mil dollars as of 2 December 2022. Raymond Vennare owns over 5,000 units of Predictive Oncology stock worth over $79,544 and over the last 3 years Raymond sold POAI stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Raymond Vennare POAI stock SEC Form 4 insiders trading

Raymond has made over 1 trades of the Predictive Oncology stock since 2022, according to the Form 4 filled with the SEC. Most recently Raymond bought 5,000 units of POAI stock worth $2,600 on 2 December 2022.

The largest trade Raymond's ever made was buying 5,000 units of Predictive Oncology stock on 2 December 2022 worth over $2,600. On average, Raymond trades about 625 units every 0 days since 2021. As of 2 December 2022 Raymond still owns at least 83,730 units of Predictive Oncology stock.

You can see the complete history of Raymond Vennare stock trades at the bottom of the page.

What's Raymond Vennare's mailing address?

Raymond's mailing address filed with the SEC is 2915 COMMERS DRIVE, SUITE 900, EAGAN, MN, 55121.

Insiders trading at Predictive Oncology

Over the last 5 years, insiders at Predictive Oncology have traded over $30,944 worth of Predictive Oncology stock and bought 417,770 units worth $148,589 . The most active insiders traders include Carl I. Schwartz, J Melville Engle y Charles Lee Sr Nuzum. On average, Predictive Oncology executives and independent directors trade stock every 71 days with the average trade being worth of $29,495. The most recent stock trade was executed by Robert L Myers on 25 September 2023, trading 1,667 units of POAI stock currently worth $1,584.

What does Predictive Oncology do?

Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient's body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.

Complete history of Raymond Vennare stock trades at Predictive Oncology

Predictive Oncology executives and stock owners

Predictive Oncology executives and other stock owners filed with the SEC include:

• Dr. Carl I. Schwartz,
  CEO & Director
• Robert L. Myers,
  CFO & Sec.
• David Johnson,
  Senior Vice President - Operations
• Robert Myers,
  Chief Financial Officer
• J. Melville Engle,
  Chairman & CEO
• Richard L. Gabriel B.Sc, MBA,
  Sr. VP of R&D
• Gregory St.Clair,
  Independent Director
• Chuck Nuzum,
  Independent Director
• Nancy Chung-Welch,
  Independent Director
• Frank Mancuso,
  Director
• Timothy Krochuk,
  Director
• Ricardo Koenigsberger,
  Director
• Daniel Handley,
  Director
• H. Gabriel,
  Director
• J. Engle,
  Director
• Carl Schwartz,
  President, Chief Executive Officer, Director
• Dr. Arlette H. Uihlein FCAP, M.D.,
  Sr. VP of Regulatory Affairs & Quality
• Theresa Ferguson,
  Sr. Director of Marketing
• Dr. Julia Kirshner Ph.D.,
  Chief Scientific Officer
• Dr. Lawrence J. DeLucas D.Sc, O.D, Ph.D.,
  Sr. VP of Operations
• Pamela Bush M.B.A., Ph.D.,
  Sr. VP of Strategic Sales & Bus. Devel.
• Kevin Hungerford,
  VP of Sales & Marketing
• David Stewart Smith,
  
• Thomas J. Mc Goldrick,
  Director
• Gerald J Jr Vardzel,
  Director
• Veena Rao,
  Director
• Pamela S Prior,
  Director
• Charles Lee Sr Nuzum,
  Director
• Matthew Hawryluk,
  Director
• Christina Lee Md Jenkins,
  
• Raymond F Vennare,
  CHIEF EXECUTIVE OFFICER